keyword
MENU ▼
Read by QxMD icon Read
search

macular edema

keyword
https://www.readbyqxmd.com/read/28917401/pseudophakic-cystoid-macular-edema-and-spectral-domain-optical-coherence-tomography-detectable-central-macular-thickness-changes-with-perioperative-prostaglandin-analogs
#1
Andrew Walkden, Louise F Porter, Jiten Morarji, Simon P Kelly, Evangelos Sioras
PURPOSE: To define the incidence of cystoid macular edema (CME) and spectral-domain optical coherence tomography-detectable (SD-OCT) subclinical changes in central retinal thickness in patients using prostaglandin analog (PGA) eyedrops after phacoemulsification. SETTING: Manchester Royal Eye Hospital, Manchester, United Kingdom. DESIGN: Prospective case series. METHODS: A consecutive analysis of the incidence of postoperative CME after phacoemulsification by a single surgeon was performed in eyes of patients using PGA eyedrops between March 2010 and January 2014...
August 2017: Journal of Cataract and Refractive Surgery
https://www.readbyqxmd.com/read/28916115/-retinal-vein-occlusions
#2
REVIEW
A Pierru, J-F Girmens, E Héron, M Paques
Retinal venous occlusions comprise central retinal vein occlusion, hemiretinal vein occlusions, and branch retinal vein occlusions. They are associated with arterial hypertension and glaucoma. Retinal vein occlusions occur more frequently in males, at a median age of 55. The pathogenesis of retinal venous occlusions remains obscure. The clinical presentation of the disease is variable. In most cases, there is a unilateral visual loss over days with a painless, white and quiet eye. However, retinal venous occlusions may also present as an abrupt and profound loss of vision, or be asymptomatic...
September 12, 2017: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/28914687/prevention-of-macular-edema-after-cataract-surgery
#3
Laura H P Wielders, Jan S A G Schouten, Rudy M M A Nuijts
PURPOSE OF REVIEW: Although cataract surgery can effectively restore visual function in many patients with cataract, pseudophakic cystoid macular edema (PCME) remains an important cause of suboptimal visual acuity. The present review provides an overview of the current literature on the prevention and treatment of PCME. RECENT FINDINGS: Optimal prevention of PCME starts preoperatively with a personalized risk assessment. Diabetes mellitus, retinal vein occlusion, epiretinal membrane, macular hole, and uveitis are the most important risk factors for developing cystoid macular edema after cataract surgery...
September 12, 2017: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/28913997/additive-effect-of-oral-steroid-with-topical-nonsteroidal-anti-inflammatory-drug-for-preventing-cystoid-macular-edema-after-cataract-surgery-in-patients-with-epiretinal-membrane
#4
Seonghwan Kim, Mee Kum Kim, Won Ryang Wee
PURPOSE: To investigate the additive effect of oral steroid with topical nonsteroidal anti-inflammatory drug (NSAID) on cystoid macular edema (CME) in patients with epiretinal membrane (ERM) after cataract surgery. METHODS: Medical records of subjects who underwent uneventful cataract surgery (n = 1,349) were retrospectively reviewed; among these patients, those with pre-existing ERM (n = 81) were included. Patients were divided into two groups: one group had postoperative administration of oral steroid for 1 week (n = 45) and the other group did not have oral steroid administration (n = 36)...
August 18, 2017: Korean Journal of Ophthalmology: KJO
https://www.readbyqxmd.com/read/28905255/benefit-risk-profile-of-sphingosine-1-phosphate-receptor-modulators-in-relapsing-and-secondary-progressive-multiple-sclerosis
#5
Giancarlo Comi, Hans-Peter Hartung, Rajesh Bakshi, Ian M Williams, Heinz Wiendl
Since the approval of fingolimod, several selective sphingosine-1-phosphate receptor modulators have entered clinical development for multiple sclerosis. However, side effects can occur with sphingosine-1-phosphate receptor modulators. By considering short-term data across the drug class and longer term fingolimod data, we aim to highlight the potential of sphingosine-1-phosphate receptor modulators in multiple sclerosis, while offering reassurance that their benefit-risk profiles are suitable for long-term therapy...
September 13, 2017: Drugs
https://www.readbyqxmd.com/read/28904960/mystery-of-retinal-vein-occlusion-vasoactivity-of-the-vein-and-possible-involvement-of-endothelin-1
#6
REVIEW
Teruyo Kida
Retinal vein occlusion (RVO) is a common vascular disease of retina; however, the pathomechanism leading to RVO is not yet clear. In general, increasing age, hypertension, arteriosclerosis, diabetes mellitus, dyslipidemia, cardiovascular disorder, and cerebral stroke are systemic risk factors of RVO. However, RVO often occur in the unilateral eye and sometimes develop in young subjects who have no arteriosclerosis. In addition, RVO show different variations on the degrees of severity; some RVO are resolved without any treatment and others develop vision-threatening complications such as macular edema, combined retinal artery occlusion, vitreous hemorrhage, and glaucoma...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28902336/switching-anti-vegf-drugs-in-the-treatment-of-diabetic-macular-edema
#7
Touka Banaee, Mohammed Ashraf, Felipe F Conti, Rishi P Singh
Since their introduction in the late 2000s, anti-vascular endothelial growth factor (VEGF) agents have become the first-line choice for center-involved diabetic macular edema (DME). Even with its proven effectiveness, there are still cases that do not respond satisfactorily. In those cases, a treatment option is to change to another anti-VEGF drug. In this paper, the authors review studies on switching between different anti-VEGF drugs in the treatment of persistent DME. An extensive bibliographic review was done using PubMed, Embase, and Scopus...
September 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28902334/multicenter-randomized-clinical-trial-to-assess-the-effectiveness-of-intravitreal-injections-of-bevacizumab-triamcinolone-or-their-combination-in-the-treatment-of-diabetic-macular-edema
#8
Hermelino O Neto, Caio V Regatieri, Mário J Nobrega, Cristina Muccioli, Antonio M Casella, Rafael E Andrade, Mauricio Maia, Vinicius Kniggendorf, Magno Ferreira, André C Branco, Rubens Belfort
BACKGROUND AND OBJECTIVE: To evaluate the efficacy of combined bevacizumab-triamcinolone intravitreal injection in the treatment of diabetic macular edema (DME) compared to monotherapy. PATIENTS AND METHODS: At eight clinical sites, 111 patients with DME were randomly assigned to receive an intravitreal injection of bevacizumab (Avastin; Genentech, South San Francisco, CA), triamcinolone (Ophthalmos Pharmaceutical Industry, São Paulo-SP, Brazil), or their combination...
September 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28902332/high-dose-decanted-triamcinolone-for-treatment-resistant-persistent-macular-edema
#9
Ilkay Kilic Muftuoglu, Frank F Tsai, Tiezhu Lin, William R Freeman
BACKGROUND AND OBJECTIVE: To report the outcomes of decanted high-dose intravitreal triamcinolone acetonide (HD-IVTA) injection for treatment-resistant persistent macular edema (ME). PATIENTS AND METHODS: Seventy-seven eyes of 70 consecutive patients who failed prior treatments for persistent ME received as-needed HD-IVTA injections. Best-corrected visual acuity and central macular thickness (CMT) were assessed at all follow-up visits. RESULTS: Thirty-three eyes (42...
September 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28902097/retinal-microvasculature-and-visual-acuity-after-intravitreal-aflibercept-in-eyes-with-central-retinal-vein-occlusion-an-optical-coherence-tomography-angiography-study
#10
Andrew Winegarner, Taku Wakabayashi, Chikako Hara-Ueno, Tatsuhiko Sato, Caleb Busch, Yoko Fukushima, Kaori Sayanagi, Kentaro Nishida, Hirokazu Sakaguchi, Kohji Nishida
PURPOSE: To investigate vascular perfusion and foveal avascular zone area in the superficial capillary plexus (SCP) and deep capillary plexus (DCP) after intravitreal aflibercept therapy in central retinal vein occlusion eyes and their association with best-corrected visual acuity. METHODS: Thirty-five subjects with central retinal vein occlusion and macular edema were evaluated. After macular edema resolution following intravitreal aflibercept, subjects underwent optical coherence tomography angiography to measure SCP and DCP perfusion and the foveal avascular zone within a 3 × 3-mm area...
September 7, 2017: Retina
https://www.readbyqxmd.com/read/28900543/switching-to-aflibercept-in-diabetic-macular-edema-not-responding-to-ranibizumab-and-or-intravitreal-dexamethasone-implant
#11
Antoine Herbaut, Franck Fajnkuchen, Lise Qu-Knafo, Sylvia Nghiem-Buffet, Bahram Bodaghi, Audrey Giocanti-Auregan
PURPOSE: To assess short-term functional and anatomical outcomes of refractory diabetic macular edema (DME) following a switch from ranibizumab or dexamethasone to aflibercept. METHODS: We included retrospectively eyes with persistent DME after at least 3 ranibizumab and/or one dexamethasone implant intravitreal injections (IVI). The primary endpoint was the mean change in visual acuity (VA) at month 6 (M6) after switching. RESULTS: Twenty-five eyes were included...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28898111/complications-of-scleral-fixated-intraocular-lenses
#12
Emma C Davies, Roberto Pineda
INTRODUCTION: Understanding the evolution of complications after scleral-fixated lens placement demonstrates advantageous surgical techniques and suitable candidates. MATERIALS/METHODS: A literature search in PubMed for several terms, including "scleral intraocular lens complication," yielded 17 relevant articles. RESULTS: Reviewing complication trends over time, lens tilt and suture erosion have decreased, cystoid macular edema has increased, and retinal detachment has remained the same after scleral-fixated lens placement...
September 12, 2017: Seminars in Ophthalmology
https://www.readbyqxmd.com/read/28885255/current-and-emerging-treatment-for-diabetic-macular-edema
#13
Cindy Ung, Durga S Borkar, Lucy H Young
No abstract text is available yet for this article.
2017: International Ophthalmology Clinics
https://www.readbyqxmd.com/read/28884024/combined-phacoemulsification-and-intravitreal-dexamethasone-implant-ozurdex%C3%A2-in-diabetic-patients-with-coexisting-cataract-and-diabetic-macular-edema
#14
Claudio Furino, Francesco Boscia, Alfredo Niro, Ermete Giancipoli, Maria Oliva Grassi, Giuseppe D'amico Ricci, Francesco Blasetti, Michele Reibaldi, Giovanni Alessio
PURPOSE: To investigate the effectiveness and safety of combined phacoemulsification and dexamethasone intravitreal implant in patients with cataract and diabetic macular edema. METHODS: In this two-center, retrospective, single-group study, the charts of 16 consecutive patients who underwent combined phacoemulsification and intravitreal dexamethasone implant were retrospectively reviewed. These 16 patients, 7 men and 9 women, were observed at least 3 months of follow-up...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28883712/integrated-results-from-the-copernicus-and-galileo-studies
#15
Amelie Pielen, W Lloyd Clark, David S Boyer, Yuichiro Ogura, Frank G Holz, Jean-Francois Korobelnik, Brigitte Stemper, Friedrich Asmus, Kay D Rittenhouse, Christiane Ahlers, Robert Vitti, Namrata Saroj, Oliver Zeitz, Julia A Haller
OBJECTIVES: To report on the efficacy and safety of intravitreal aflibercept in patients with macular edema secondary to central retinal vein occlusion (CRVO) in an integrated analysis of COPERNICUS and GALILEO. PATIENTS AND METHODS: Patients were randomized to receive intravitreal aflibercept 2 mg every 4 weeks or sham injections until week 24. From week 24 to week 52, all intravitreal aflibercept-treated patients in both studies and sham-treated patients in COPERNICUS were eligible to receive intravitreal aflibercept based on prespecified criteria...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28882393/-prognostic-factors-in-uveitis
#16
N Albaroudi, M Tijani, N Boutimzine, O Cherkaoui, M Laghmari
PURPOSE: To evaluate prognostic factors of vision loss among patients with uveitis. MATERIAL AND METHODS: This descriptive and retrospective study included all patients diagnosed with uveitis who were seen at the teaching hospital of Rabat, Morocco, over a 5-year period. Information regarding demographic data, uveitis type, bilaterality of the disease, etiology and complications were gathered from patients' records. Statistical analysis was performed using SPSS software...
September 4, 2017: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/28881150/patterns-of-retinal-thickness-prior-to-and-following-treatment-with-fluocinolone-acetonide-190%C3%A2-%C3%A2%C2%B5g-intravitreal-implant-for-diabetic-macular-edema
#17
Craig J Currie, Sarah E Holden, David R Owens
OBJECTIVES: To compare retinal thickness before and after treatment with the fluocinolone acetonide (FAc) 190 µg intravitreal implant in people with diabetic macular edema (DME) using data from the Iluvien Clinical Evidence study in the UK (ICE-UK). METHODS: For this retrospective cohort study, data on people attending any one of 13 participating ophthalmology departments and treated with FAc intravitreal implant between April 1, 2013 and April 15, 2015 were collected for 12 months prior to and at least 12 months after implantation...
September 7, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28881149/evaluation-of-the-clinical-effectiveness-in-routine-practice-of-fluocinolone-acetonide-190%C3%A2-%C3%A2%C2%B5g-intravitreal-implant-in-people-with-diabetic-macular-edema
#18
Sarah E Holden, Craig J Currie, David R Owens
OBJECTIVE: The aim of the Iluvien Clinical Evidence study in the UK (ICE-UK) was to assess the real-world effectiveness of fluocinolone acetonide (FAc) 190 µg intravitreal implant for the treatment of clinically significant chronic diabetic macular edema (DME) in routine clinical practice. METHODS: This retrospective study collected data from patient medical records in 13 ophthalmology centers for people with DME prescribed FAc intravitreal implant between April 1, 2013 and April 15, 2015...
September 7, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28881146/health-economic-evaluation-of-fluocinolone-acetonide-190%C3%A2-%C3%A2%C2%B5g-implant-in-people-with-diabetic-macular-edema
#19
Sarah E Holden, Craig J Currie, David R Owens
OBJECTIVES: To assess healthcare resource use and costs of treating people with clinically significant diabetic macular edema (DME) with fluocinolone acetonide (FAc) 190 µg intravitreal implant in routine clinical practice. METHODS: The retrospective Iluvien Clinical Evidence (ICE-UK) study collected data on people prescribed the FAc implant in any one of 13 ophthalmology centers between April 1, 2013 and April 15, 2015. Data were collected for 12 months before and after implantation...
September 7, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28881143/evaluation-of-the-clinical-effectiveness-of-fluocinolone-acetonide-190%C3%A2-%C3%A2%C2%B5g-intravitreal-implant-in-diabetic-macular-edema-a-comparison-between-study-and-fellow-eyes
#20
Craig J Currie, Sarah E Holden, Ellen Berni, David R Owens
OBJECTIVES: To compare visual and anatomical outcomes between eyes treated with fluocinolone acetonide (FAc) 190 µg intravitreal implant for clinically significant chronic diabetic macular edema (DME) and fellow eyes not treated with FAc implant using data from the Iluvien Clinical Evidence study in the UK (ICE-UK) study. METHODS: In this retrospective cohort study, data on people attending hospital eye services and treated with the FAc implant between April 1, 2013 and April 15, 2015 were collected...
September 7, 2017: Current Medical Research and Opinion
keyword
keyword
106204
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"